While cHL demonstrates remarkable responsiveness to checkpoint inhibition, owing primarily to its characteristic amplification of PD-L1 and PD-L2, other malignancies such as NHL, AML, and MM exhibit more heterogeneous and often limited responses. Here, PDCD1LG2 is linked to non-Hodgkin lymphoma.